RNA synthesis inhibitors increase melatonin production in Y79 human retinoblastoma cells

Jina L. Janavs, Mary E. Pierce, Joseph S. Takahashi

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Y79 human retinoblastoma cells synthesize melatonin in cell culture thus providing a unique preparation for studying the regulation of melatonin biosynthesis in mammalian retinas. We have previously demonstrated that Y79 cells express NAT and HIOMT activity and produce melatonin in a cAMP- and protein synthesis-dependent manner by increasing NAT, and not HIOMT activity, as has been demonstrated in other retinal and pineal melatonin synthesizing systems. We have extended these studies to investigate the role of RNA synthesis in melatonin regulation, and report here that RNA synthesis inhibitors do not suppress melatonin production in Y79 retinoblastoma cells. Rather, at intermediate concentrations, the inhibitors actinomycin D and camptothecin increase melatonin levels. Camptothecin, a topoisomerase I inhibitor, also increased NAT activity and accumulated cAMP levels in a calcium-dependent manner. This effect on cAMP did not appear to occur through phosphodiesterase, and other regulators of retinal melatonin such as melatonin degradation or components of the dopamine system were unaffected. These results are in contrast with the suppression of melatonin synthesis by RNA synthesis inhibitors observed in rat and chick pineal glands and in chick retinas.

Original languageEnglish (US)
Pages (from-to)47-56
Number of pages10
JournalMolecular Brain Research
Volume23
Issue number1-2
DOIs
StatePublished - Apr 1994

Keywords

  • Actinomycin D
  • Camptothecin
  • Melatonin
  • N-Acetyltransferase
  • RNA synthesis
  • Retinoblastoma
  • cAMP

ASJC Scopus subject areas

  • Molecular Biology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'RNA synthesis inhibitors increase melatonin production in Y79 human retinoblastoma cells'. Together they form a unique fingerprint.

  • Cite this